Health Care

Jaguar Health’s new one‑time stock dividend shows its commitment to shareholders amid a challenging financial climate, highlighting its natural‑pharma focus and future growth prospects.

Vistagen Therapeutics faces a federal securities class action while gearing up to present its intranasal “pherines” at the TD Cowen Healthcare Conference, leaving investors to weigh legal risks against potential neuropharmacology breakthroughs and a…

Opus Genetics reports promising Phase 1/2 BEST1 gene‑therapy results and FDA acceptance of a new phentolamine eye solution for presbyopia, boosting its vision‑therapy pipeline.

ALX Oncology’s 2025 results show a return to profitability, a $150 million capital raise, and promising progress in evorpacept and ALX2004 trials – key insights for investors and oncology stakeholders.

Discover Photocure ASA: Norway’s pharma leader behind Hexvix, Cevira and Visonac, its market outlook, stock insights, and future growth potential.

BrightSpring Health Services Q4 2025 earnings reveal a 10.8 % revenue rise and 331 % EPS jump, with 2026 guidance forecasting $13.9 B revenue and $1.78 EPS—driven by AI‑powered care platforms and expanding behavioral‑health services.

AbbVie 2026 outlook: high‑cap pharma leader with $380 m manufacturing expansion, AI‑driven pipeline, and “Outperform” analyst support—investors weigh robust growth vs. lofty PE.

Health Catalyst appoints new CEO Ben Albert amid volatile $1.73 stock; learn how the Utah‑based health‑software firm plans to stabilize its market and drive innovation.

ImExHS Limited reports FY25 results: $29 M revenue, 10 % growth, rising EBITDA, strong user engagement, and top‑end performance in the global healthcare imaging market.

Explore HCA Healthcare’s 2026 updates: new executive incentive program, conference plans, and historic growth—key insights for investors and health‑care stakeholders.